These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 37338150)

  • 1. Safety, Tolerability, and Pharmacokinetics of Senaparib, a Novel PARP1/2 Inhibitor, in Chinese Patients With Advanced Solid Tumors: A Phase I Trial.
    Cao J; Guo H; Ji D; Shen W; Zhang S; Hsieh CY; Xiong Cai S; Edward Tian Y; Xu C; Zhang P; Xu B
    Oncologist; 2023 Dec; 28(12):e1259-e1267. PubMed ID: 37338150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 1 dose-escalation study of the poly(ADP-ribose) polymerase inhibitor senaparib in Australian patients with advanced solid tumors.
    Gao B; Voskoboynik M; Cooper A; Wilkinson K; Hoon S; Hsieh CY; Cai S; Tian YE; Bao J; Ma N; Wang C; Zhang M; Li B; Guo M; Zhou R; Wang X; Xu C; de Souza P
    Cancer; 2023 Apr; 129(7):1041-1050. PubMed ID: 36718624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, pharmacokinetics, and preliminary efficacy of the PARP inhibitor talazoparib in Japanese patients with advanced solid tumors: phase 1 study.
    Naito Y; Kuboki Y; Ikeda M; Harano K; Matsubara N; Toyoizumi S; Mori Y; Hori N; Nagasawa T; Kogawa T
    Invest New Drugs; 2021 Dec; 39(6):1568-1576. PubMed ID: 34160752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial.
    Wu X; Liu J; Wang J; Wang L; Lin Z; Wang X; Zhu J; Kong B; Fei J; Tang Y; Xia B; Liang Z; Wang K; Huang Y; Zheng H; Lin A; Jiang K; Wang W; Wang X; Lou G; Pan H; Yao S; Li G; Hao M; Cai Y; Chen X; Yang Z; Chen Y; Wen H; Qu P; Xu C; Hsieh CY;
    Nat Med; 2024 Jun; 30(6):1612-1621. PubMed ID: 38750351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.
    Sandhu SK; Schelman WR; Wilding G; Moreno V; Baird RD; Miranda S; Hylands L; Riisnaes R; Forster M; Omlin A; Kreischer N; Thway K; Gevensleben H; Sun L; Loughney J; Chatterjee M; Toniatti C; Carpenter CL; Iannone R; Kaye SB; de Bono JS; Wenham RM
    Lancet Oncol; 2013 Aug; 14(9):882-92. PubMed ID: 23810788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase I Dose-Escalation Study of LY3405105, a Covalent Inhibitor of Cyclin-Dependent Kinase 7, Administered to Patients With Advanced Solid Tumors.
    Garralda E; Schram AM; Bedard PL; Schwartz GK; Yuen E; McNeely SC; Ribeiro S; Cunningham J; Wang Y; Urunuela A; Xu X; LoRusso P
    Oncologist; 2024 Jan; 29(1):e131-e140. PubMed ID: 37531083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 1b study to assess the safety, tolerability, and clinical activity of pamiparib in combination with temozolomide in patients with locally advanced or metastatic solid tumors.
    Stradella A; Johnson M; Goel S; Park H; Lakhani N; Arkenau HT; Galsky MD; Calvo E; Baz V; Moreno V; Saavedra O; Luen SJ; Mu S; Wan Q; Chang V; Zhang W; Barve M
    Cancer Med; 2024 Jul; 13(13):e7385. PubMed ID: 38970256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.
    Gray HJ; Bell-McGuinn K; Fleming GF; Cristea M; Xiong H; Sullivan D; Luo Y; McKee MD; Munasinghe W; Martin LP
    Gynecol Oncol; 2018 Mar; 148(3):507-514. PubMed ID: 29352572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer.
    van der Biessen DAJ; Gietema JA; de Jonge MJA; Desar IME; den Hollander MW; Dudley M; Dunbar M; Hetman R; Serpenti C; Xiong H; Mittapalli RK; Timms KM; Ansell P; Ratajczak CK; Shepherd SP; van Herpen CML
    Invest New Drugs; 2018 Oct; 36(5):828-835. PubMed ID: 29313279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours.
    Lickliter JD; Voskoboynik M; Mileshkin L; Gan HK; Kichenadasse G; Zhang K; Zhang M; Tang Z; Millward M
    Br J Cancer; 2022 Mar; 126(4):576-585. PubMed ID: 34795408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline
    de Bono J; Ramanathan RK; Mina L; Chugh R; Glaspy J; Rafii S; Kaye S; Sachdev J; Heymach J; Smith DC; Henshaw JW; Herriott A; Patterson M; Curtin NJ; Byers LA; Wainberg ZA
    Cancer Discov; 2017 Jun; 7(6):620-629. PubMed ID: 28242752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
    Friedlander M; Meniawy T; Markman B; Mileshkin L; Harnett P; Millward M; Lundy J; Freimund A; Norris C; Mu S; Wu J; Paton V; Gao B
    Lancet Oncol; 2019 Sep; 20(9):1306-1315. PubMed ID: 31378459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies.
    Appleman LJ; Beumer JH; Jiang Y; Lin Y; Ding F; Puhalla S; Swartz L; Owonikoko TK; Donald Harvey R; Stoller R; Petro DP; Tawbi HA; Argiris A; Strychor S; Pouquet M; Kiesel B; Chen AP; Gandara D; Belani CP; Chu E; Ramalingam SS
    Cancer Chemother Pharmacol; 2019 Dec; 84(6):1289-1301. PubMed ID: 31549216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysis.
    Liu Y; Wang W; Yin R; Zhang Y; Zhang Y; Zhang K; Pan H; Wang K; Lou G; Li G; Zhang R; Li K; Rao J; Zhang B; Wang Y; Wang Q; Gao Y; Li H
    BMC Med; 2023 Sep; 21(1):376. PubMed ID: 37775744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pamiparib dose escalation in Chinese patients with non-mucinous high-grade ovarian cancer or advanced triple-negative breast cancer.
    Xu B; Yin Y; Dong M; Song Y; Li W; Huang X; Wang T; He J; Mu X; Li L; Mu S; Zhang W; Li M
    Cancer Med; 2021 Jan; 10(1):109-118. PubMed ID: 33128299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.
    Tutt A; Robson M; Garber JE; Domchek SM; Audeh MW; Weitzel JN; Friedlander M; Arun B; Loman N; Schmutzler RK; Wardley A; Mitchell G; Earl H; Wickens M; Carmichael J
    Lancet; 2010 Jul; 376(9737):235-44. PubMed ID: 20609467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First phase 1 clinical study of olaparib in pediatric patients with refractory solid tumors.
    Takagi M; Ogawa C; Iehara T; Aoki-Nogami Y; Ishibashi E; Imai M; Kimura T; Nagata M; Yasuhara M; Masutani M; Yoshimura K; Tomizawa D; Ogawa A; Yonemori K; Morishita A; Miyamoto S; Takita J; Kihara T; Nobori K; Hasebe K; Miya F; Ikeda S; Shioda Y; Matsumoto K; Fujimura J; Mizutani S; Morio T; Hosoi H; Koike R
    Cancer; 2022 Aug; 128(15):2949-2957. PubMed ID: 35593736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study.
    Czito BG; Deming DA; Jameson GS; Mulcahy MF; Vaghefi H; Dudley MW; Holen KD; DeLuca A; Mittapalli RK; Munasinghe W; He L; Zalcberg JR; Ngan SY; Komarnitsky P; Michael M
    Lancet Gastroenterol Hepatol; 2017 Jun; 2(6):418-426. PubMed ID: 28497757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CEP-9722 (a PARP-1 and PARP-2 inhibitor) in combination with gemcitabine and cisplatin in patients with advanced solid tumors.
    Awada A; Campone M; Varga A; Aftimos P; Frenel JS; Bahleda R; Gombos A; Bourbouloux E; Soria JC
    Anticancer Drugs; 2016 Apr; 27(4):342-8. PubMed ID: 26796987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Food on the Pharmacokinetics of Senaparib (IMP4297) in Healthy Chinese Subjects.
    Meng X; Lin X; Jiang R; Lu Y; Zeng L; Cao M; Zhang J
    Clin Drug Investig; 2022 Nov; 42(11):1009-1016. PubMed ID: 36239914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.